Cargando…
Corrigendum: Comparing progression biomarkers in clinical trials of early Alzheimer’s disease
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886035/ https://www.ncbi.nlm.nih.gov/pubmed/33440069 http://dx.doi.org/10.1002/acn3.51295 |
Ejemplares similares
-
Epigenetic mechanisms in Alzheimer’s disease [Corrigendum]
Publicado: (2014) -
Serum miR-128 Serves as a Potential Diagnostic Biomarker for Alzheimer’s Disease [Corrigendum]
Publicado: (2021) -
Speech and orofacial apraxias in Alzheimer's disease – CORRIGENDUM
por: Cera, Maysa Luchesi, et al.
Publicado: (2013) -
Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trials
por: Jimenez-Maggiora, Gustavo A, et al.
Publicado: (2022) -
Corrigendum: Amyloid and tau positive mild cognitive impairment: clinical and biomarker characteristics of dementia progression
Publicado: (2021)